tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Checkpoint Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Checkpoint Therapeutics (CKPT) to Neutral from Buy with a price target of $4.10, down from $20, following the acquisition by Sun Pharmaceuticals. The is “please with the outcome,” noting Checkpoint is being acquired at $4.10 per share and a 70c contingent value right.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1